A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers

Author： Goel Sanjay   Desai Kavita   Macapinlac Manuel   Wadler Scott   Goldberg Gary   Fields Abbie   Einstein Mark   Volterra Fabio   Wong Benny   Martin Russell   Mani Sridhar  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.24, Iss.2, 2006-03, pp. : 125-134

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3481-3490

Blackwell Publishing

Access to resources Recommend Favorite

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study

By Blais Normand   Camidge D.   Jonker Derek   Soulières Denis   Laurie Scott   Diab Sami   Ruiz-Garcia Ana   Thall Aron   Zhang Ke   Chao Richard   Chow Laura  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1487-1498

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors

By Camacho Luis   Olson Jon   Tong William   Young Charles   Spriggs David   Malkin Mark  

Investigational New Drugs, Vol. 25, Iss. 2, 2007-04 ,pp. : 131-138

Springer Publishing Company

Access to resources Recommend Favorite

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer

By Advani Ranjana   Lum Bert   Fisher George   Halsey Joanne   Geary Richard   Holmlund Jon   Kwoh T.   Dorr F.   Sikic Branimir  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 467-477

Springer Publishing Company

Access to resources Recommend Favorite

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

By Hollebecque A.   Deutsch E.   Massard C.   Gomez-Roca C.   Bahleda R.   Ribrag V.   Bourgier C.   Lazar V.   Lacroix L.   Gazzah A.   Varga A.   Baere T.   Beier F.   Kroesser S.   Trang K.   Zenke F.   Klevesath M.   Soria Jean-Charles  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1530-1538

Springer Publishing Company

Access to resources Recommend Favorite